Myron Cohen, MD, director of the UNC Institute for Global Health and Infectious Diseases, co-authored a piece for JAMA Network, along with colleagues from the National Institutes of Health, on monoclonal antibodies as potentially therapeutic and prophylactic applications.
Myron Cohen, MD, Associate Vice Chancellor for Global Health and Medical Affairs; the Yeargan-Bate Distinguished Professor of Medicine, Microbiology and Immunology, and Epidemiology; and Director, Institute for Global Health & Infectious Diseases at UNC-Chapel Hill, co-wrote an article on monoclonal antibodies with colleagues Mary Marovich, MD, and John Mascola, MD, both from the Vaccine Research Program at the National Institute of Allergy and Infectious Diseases.
During the COVID-19 pandemic, “attention has focused on the development of vaccines, new antiviral agents, and convalescent plasma infusions. Monoclonal antibodies have received less attention even though neutralizing antibodies are a key component of protective immunity for most viral diseases. Neutralizing monoclonal antibodies to SARS-CoV-2 have the potential for both therapeutic and prophylactic applications, and can help to guide vaccine design and development.”
Read the rest of the article.